Scribble

APMD share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Price change

The price of APMD shares has increased $0.94 since the market last closed. This is a 6.64% rise.
Closed at $15.10.

The stock has remained unchanged in after-hours trading.

Key terms

Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $628.62M

A market capitalization between $300 million and $2 billion places APMD in the small capitalization category.

Key terms

Smart score

Oct 12, 2026 8:45am ET Bank of America Securities Remains a Buy on Apnimed, Inc. (APMD) by TipRanks Oct 06, 2026 5:58am ET Bank of America Puts These 2 Under-the-Radar IPO Stocks on Its Buy List by TipRanks Sep 09, 2026 9:15am ET Apnimed: Buy Rating Reiterated on Strong Oxnimbi OSA Profile and Unchanged $50 Price Target by TipRanks Aug 30, 2026 9:20am ET Wall Street Analysts Are Bullish on Top NA Picks by TipRanks Aug 25, 2026 7:20am ET Apnimed initiated with an Overweight at Cantor Fitzgerald by TipRanks Aug 25, 2026 6:35am ET Apnimed initiated with an Overweight at Cantor Fitzgerald by TipRanks Aug 25, 2026 6:28am ET Apnimed, Inc. (APMD) Receives a Buy from LifeSci Capital by TipRanks Aug 25, 2026 6:26am ET Oxnimbi’s Strong Phase 3 Data and Large OSA Market Opportunity Drive Brisebois Buy Rating with $50 Price Target by TipRanks Aug 25, 2026 6:25am ET Apnimed initiated with an Outperform at Evercore ISI by TipRanks Aug 25, 2026 6:20am ET Apnimed initiated with an Outperform at LifeSci Capital by TipRanks Aug 25, 2026 6:15am ET Apnimed initiated with a Buy at BofA by TipRanks Aug 24, 2026 10:45am ET Opening Day: Lyntris lags in debut, OpenAI reaffirms 2027 IPO plans by TipRanks Aug 03, 2026 10:08pm ET Insider Move: Apnimed Director Makes Bold New Investment by TipRanks Aug 03, 2026 11:31am ET Opening Day: Soft debuts for Jersey Mike’s, Reformation by TipRanks Jul 31, 2026 12:15pm ET Apnimed opens at $22.00, IPO priced at $16.00 by TipRanks Jul 31, 2026 7:05am ET Apnimed 12M share IPO priced at $16.00 by TipRanks

Nov 05, 2026 4:05pm ET Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) by GlobeNewswire Oct 12, 2026 4:05pm ET Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026 by GlobeNewswire Oct 02, 2026 4:05pm ET Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) by GlobeNewswire Sep 08, 2026 4:39pm ET Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update by GlobeNewswire Sep 04, 2026 4:01pm ET Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) by GlobeNewswire Aug 03, 2026 4:35pm ET Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire

1-year income & revenue

APMD total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
APMD net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
APMD earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

How competitors are chosen

APMD's competitors are included in the Health Technology sector and Biotechnology group
Market cap: $628.62M

A market capitalization between $300 million and $2 billion places APMD in the small capitalization category.